Zurich Cantonal Bank
XERS icon

Zurich Cantonal Bank’s Xeris Biopharma Holdings XERS Stock Holding History

Zurich Cantonal Bank’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Sell
46,100
-47,202
-51% -$301K ﹤0.01% 2105
2026
Q1 		$541K Buy
93,302
+27,535
+42% +$183K ﹤0.01% 1793
2025
Q4 		$516K Buy
65,767
+33,115
+101% +$261K ﹤0.01% 1765
2025
Q3 		$266K Buy
32,652
+29,353
+890% +$195K ﹤0.01% 2064
2025
Q2 		$15.4K Sell
3,299
-365
-10% -$1.67K ﹤0.01% 2494
2025
Q1 		$20.1K Buy
+3,664
New +$14.8K ﹤0.01% 2558
2023
Q3 		– Sell
-12
Closed -$31 – 2802
2023
Q2 		$31 Hold
12
– – ﹤0.01% 2789
2023
Q1 		$20 Sell
12
-8,107
-100% -$10.1K ﹤0.01% 2847
2022
Q4 		$10.8K Sell
8,119
-1,713
-17% -$2.42K ﹤0.01% 2800
2022
Q3 		$15K Hold
9,832
– – ﹤0.01% 2838
2022
Q2 		$15K Sell
9,832
-919
-9% -$1.94K ﹤0.01% 2826
2022
Q1 		$28K Buy
+10,751
New +$26.3K ﹤0.01% 2627

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Zurich Cantonal Bank's XERS Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Xeris Biopharma Holdings (XERS) stake by 51% in Q2 2026, selling an estimated $301K and leaving 46,100 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Zurich Cantonal Bank first reported a position in XERS in Q1 2022 and has held it in 12 quarters since. The position peaked at $541K in Q1 2026. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Zurich Cantonal Bank held 46,100 shares of Xeris Biopharma Holdings worth $365K as of Q2 2026.
  • Zurich Cantonal Bank sold 47,202 Xeris Biopharma Holdings shares in Q2 2026, an estimated $301K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2105 holding.
  • Zurich Cantonal Bank first reported a position in Xeris Biopharma Holdings in Q1 2022 and has held it in 12 quarters since.
  • Zurich Cantonal Bank's Xeris Biopharma Holdings position peaked at $541K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.